In a new study entitled “The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease,” researchers report to have found a natural body producing metabolite – β-hydroxybutyrate (BHB) — capable of blocking NLRP3 inflammasome activation, a multi protein complex that promotes secretion of pro-inflammatory cytokines and is a key mediator…
A new study entitled “Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer’s disease brains” identified genomic changes in single neurons as an underlying mechanism in sporadic Alzheimer’s disease. The study was published in the journal…
A new study is now enrolling and accepting volunteers to investigate the potential of a new drug to slow the devastating effects of Alzheimer’s disease on patients’ memory and physical activity. Eligible participants include men and women with ages between 55 to 85 years old suffering from mild to severe Alzheimer’s.
Recently, a new study presented at the Annual Meeting of the Radiological Society of North America (RSNA) showed that in brains of patients affected with Alzheimer’s disease, changes in brain connections can be visualized by Magnetic resonance imaging (MRI). Alzheimer’s disease is currently estimated to affect approximately 5 million…
A study performed at Ghent University in Belgium suggests an association between language skills and the onset of Alzheimer disease symptoms. In the study, a team of both psychologists and neurologists analyzed two different groups of patients with a probable risk to develop Alzheimer’s disease and separated according to their…
A new study entitled “Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease” reports a correlation between α-synuclein and amyloid-β in the brain of patients affected by neurodegenerative diseases, such as Parkinson’s disease. The study was published in the…
A brief study entitled “Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease” identified orexin, a protein that triggers the brain to wake after sleeping, as a potential new factor in Alzheimer’s disease. The study was published in November issue of The Journal of Experimental Medicine.
Another investigational drug trial for the treatment of Alzheimer’s is set to release key findings within the next few months. Neurotrope, Inc. recently announced the closure of their Phase 2a clinical trial of Bryostatin-1, as the last patient enrolled in the study was administered the drug. The trial was conducted under an Investigational New…
In a review study entitled “Vascular risk factors and Alzheimer’s disease,” the authors perform a comprehensive retrospective of a series of studies linking Alzheimer’s disease and vascular factors. The review was published in the BMC Medicine journal. Neurodegenerative decline, characterized by dementia, is currently estimated to affect…
Cognition Therapeutics Inc. announced the discovery of a new drug target in the brain that plays a role in the development of Alzheimer’s disease, and their investigation of new drug candidates to reverse the memory loss associated with Alzheimer’s. The two studies were entitled “Alzheimer’s therapeutics targeting Amyloid beta 1-42…
Get regular updates to your inbox.